Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction.

Abstract

Recent experimental work has demonstrated that nitric oxide (NO) is the neurotransmitter responsible for cavernous smooth muscle relaxation. Different studies on the performance of the direct NO donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have had conflicting results. We performed a single-blind cross-over trial in 20 patients with erectile dysfunction of mixed etiology comparing prostaglandin E1 (PGE1) to SIN-1 at two different dosages (1 and 2 mg, respectively) in order to determine the effectiveness of SIN-1. PGE1 always achieved the best response, SIN-1 performed statistically significantly poorer irrespective of the dosage used. There were only a few side effects with no significant difference. SIN-1 is not a useful alternative to PGE1 in the treatment of erectile dysfunction.

• Authors: H E Wegner, H H Knispel, R Klän, T Meier, K Miller
• Journal: Urologia internationalis (Urol Int) Vol. 53 Issue 4 Pg. 214-6 ( 1994) ISSN: 0042-1138 [Print] Switzerland
• PMID: 7855939 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Vasodilator Agents
• linsidomine
• Molsidomine
• Alprostadil

Topics

• Adult
• Aged
• Aged, 80 and over
• Alprostadil (therapeutic use)
• Cross-Over Studies
• Erectile Dysfunction (drug therapy, etiology)
• Humans
• Male
• Medical History Taking
• Middle Aged
• Molsidomine (analogs & derivatives, therapeutic use)
• Single-Blind Method
• Time Factors
• Treatment Outcome
• Vasodilator Agents (therapeutic use)